Drug profile · INN
ripretinib
QINLOCK
ripretinib (QINLOCK) is a stem cell growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ripretinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
ripretinib (QINLOCK) is a stem cell growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Stem cell growth factor receptor inhibitor
Primary target: Platelet-derived growth factor receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ripretinib?
ripretinib (QINLOCK) is a stem cell growth factor receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ripretinib?
QINLOCK is a marketed brand name for ripretinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ripretinib?
ripretinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.